Working… Menu

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00972933
Recruitment Status : Completed
First Posted : September 9, 2009
Last Update Posted : December 7, 2017
Bristol-Myers Squibb
Information provided by (Responsible Party):
Diwakar Davar, University of Pittsburgh